Overview

Postmarketing Surveillance Study With MOBEC®

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate - the indication for MOBEC in a dose of 15 mg per day - the treatments patients were receiving before switching to 15 mg MOBEC - how treatment with 15 mg is assessed compared with previous treatment - how effective and safe treatment with 15 mg MOBEC is considered
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Meloxicam